Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to Keytruda

Akeso announced new data from a late‑stage study of its PD‑1×VEGF bispecific antibody ivonescimab in patients with biliary tract cancer enrolled only in China.

The trial showed an improvement in overall survival compared with historical benchmarks, prompting the company to highlight the benefit as a step toward competing with established immunotherapies such as Merck’s Keytruda.

Akeso’s partner Summit Therapeutics will use the results to advance the program, and the company indicated that further development plans are underway, though no regulatory filing dates were disclosed.